199 related articles for article (PubMed ID: 20036908)
1. Molecular markers for prostatic cancer.
Castelli T; Cimino S; Magno C; Morgia G
Front Biosci (Elite Ed); 2010 Jan; 2(2):641-56. PubMed ID: 20036908
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
3. Emerging biomarkers for the diagnosis and prognosis of prostate cancer.
Sardana G; Dowell B; Diamandis EP
Clin Chem; 2008 Dec; 54(12):1951-60. PubMed ID: 18927246
[TBL] [Abstract][Full Text] [Related]
4. [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].
Haese A; Graefen M; Palisaar J; Huland E; Huland H
Urologe A; 2003 Sep; 42(9):1172-87. PubMed ID: 14504750
[TBL] [Abstract][Full Text] [Related]
5. [PSA and hK2 in the diagnosis of prostate cancer].
Alapont Alacreu JM; Navarro Rosales S; Budía Alba A; España Furió F; Morera Martínez F; Jiménez Cruz JF
Actas Urol Esp; 2008 Jun; 32(6):575-88. PubMed ID: 18655340
[TBL] [Abstract][Full Text] [Related]
6. [PSA-based parameters].
Nakashima J
Nihon Rinsho; 2005 Feb; 63(2):241-6. PubMed ID: 15714973
[TBL] [Abstract][Full Text] [Related]
7. [Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer].
Mazzola CR; Ghoneim T; Shariat SF
Prog Urol; 2011 Jan; 21(1):1-10. PubMed ID: 21193139
[TBL] [Abstract][Full Text] [Related]
8. Early prediction of prostate cancer biochemical recurrence and identification of disease persistence using PSA isoforms and human kallikrein-2.
Do Carmo Silva J; Vesely S; Luksanova H; Prusa R; Babjuk M
Tumour Biol; 2021; 43(1):197-207. PubMed ID: 34486998
[TBL] [Abstract][Full Text] [Related]
9. Molecular diagnosis of prostate cancer.
Canto EI; Shariat SF; Slawin KM
Curr Urol Rep; 2004 Jun; 5(3):203-11. PubMed ID: 15161569
[TBL] [Abstract][Full Text] [Related]
10. [Molecular forms of prostate-specific antigen and human kallikrein 2 as possible indicators in prostatic carcinoma diagnosis].
Lein M; Stephan C; Jung K; Schnorr D; Loening SA
Urologe A; 2000 Jul; 39(4):313-23. PubMed ID: 10957772
[TBL] [Abstract][Full Text] [Related]
11. Beyond prostate-specific antigen: alternate serum markers.
Ramírez ML; Nelson EC; Evans CP
Prostate Cancer Prostatic Dis; 2008; 11(3):216-29. PubMed ID: 18227856
[TBL] [Abstract][Full Text] [Related]
12. [Biological markers of prostate cancer].
Seitz C; Djavan B
Ann Urol (Paris); 2006 Dec; 40(6):329-35. PubMed ID: 17214230
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for the detection and prognosis of prostate cancer.
Hernandez J; Canby-Hagino E; Thompson IM
Curr Urol Rep; 2005 May; 6(3):171-6. PubMed ID: 15869720
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
[TBL] [Abstract][Full Text] [Related]
15. PSA and other tissue kallikreins for prostate cancer detection.
Stephan C; Jung K; Lein M; Diamandis EP
Eur J Cancer; 2007 Sep; 43(13):1918-26. PubMed ID: 17689069
[TBL] [Abstract][Full Text] [Related]
16. A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions.
Zielie PJ; Mobley JA; Ebb RG; Jiang Z; Blute RD; Ho SM
J Urol; 2004 Sep; 172(3):1130-3. PubMed ID: 15311056
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
Haese A; Graefen M; Huland H; Lilja H
Curr Urol Rep; 2004 Jun; 5(3):231-40. PubMed ID: 15161573
[TBL] [Abstract][Full Text] [Related]
18. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
Bryant RJ; Sjoberg DD; Vickers AJ; Robinson MC; Kumar R; Marsden L; Davis M; Scardino PT; Donovan J; Neal DE; Lilja H; Hamdy FC
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863334
[TBL] [Abstract][Full Text] [Related]
19. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.
Ornstein DK; Rayford W; Fusaro VA; Conrads TP; Ross SJ; Hitt BA; Wiggins WW; Veenstra TD; Liotta LA; Petricoin EF
J Urol; 2004 Oct; 172(4 Pt 1):1302-5. PubMed ID: 15371828
[TBL] [Abstract][Full Text] [Related]
20. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
